

Amendments to the Claims:

Please amend claims 1, 10-12, 23, and 24 as shown in the listing of claims.

Please cancel claims 7-9, 25, and 27 without prejudice.

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A method for treating ~~a pathological condition of ocular tissue;~~ intraocular disease, herpes simplex virus-1 (HSV-1) or cytomegalovirus (CMV) retinitis or other ocular viral infections comprising ~~contacting a therapeutically active complex with ocular tissue, wherein the therapeutically active complex is 1-O-hexadecyloxypropyl-phospho-arabinofuranosylguanosine (HDP-P-Ara-G);~~ intravitreally injecting a solution of microfluidized particles of 1-O-hexadecylcycloxypropyl-cyclic-cidofovir (HDP-cCDV) or microfluidized particles of hexadecyloxypropyl-3-phosphoganciclovir (HDP-P-GCV) to the eye, wherein ~~the pathological condition is selected from the group consisting of macular degeneration, ocular proliferative or vascular diseases, and diseases of elevated intraocular pressure thereby treating the pathological condition~~ HDP-cCDV and the HDP-P-GCV particles have a volume median diameter of about 4.4 μ m, with the proviso that the method does not use liposomes.
- 2-9. (Canceled).
10. (Currently Amended) The method of claim 1, wherein ~~the therapeutically active complex is in a slurry comprising~~ microfluidized particles of HDP-cCDV and the microfluidized particles of HDP-P-GCV are in amorphous forms and/or crystalline forms.

11. (Currently Amended) The method of claim 1, wherein the ~~therapeutically active complex is~~ microfluidized particles of HDP-cCDV and the microfluidized particles of HDP-P-GCV are in substantially crystalline form.
12. (Currently Amended) The method of claim 1, wherein the ~~therapeutically active complex is~~ microfluidized particles of HDP-cCDV and the microfluidized particles of HDP-P-GCV are in substantially amorphous form.
- 13-22. (Canceled).
23. (Currently Amended) A method for the slow-release delivery of a ~~therapeutically active agent to ocular tissue, comprising contacting the ocular tissue with a therapeutically active complex, wherein the therapeutically active complex is~~ 1-O-hexadecyloxypropyl-phospho-arabinofuranosyl-guanosine (HDP-P-Ara-G), 1-O-hexadecylcyloxypropyl-cyclic-cidofovir (HDP-cCDV) or hexadecyloxypropyl-3-phospho-ganciclovir (HDP-P-GCV) to the eye, comprising intravitreally injecting a solution of microfluidized particles of HDP-P-Ara-G, or microfluidized particles of HDP-cCDV or microfluidized particles of HDP-P-GCV to the eye, wherein the therapeutically active complex comprises particles having size between about 10 nm and about 100,000 nm, thereby delivering a slow release of the therapeutically active agent to ocular tissue microfluidized particles of HDP-P-Ara-G, HDP-cCDV, and HDP-P-GCV have a volume median diameter of about 4.4 μ m, with the proviso that the method does not use liposomes.
24. (Currently Amended) A method for increasing residence time of a ~~therapeutically active agent in ocular tissue, comprising contacting a therapeutically active complex with ocular tissue, wherein the therapeutically active complex is~~ 1-O-hexadecyloxypropyl-phospho-arabinofuranosylguanosine (HDP-P-Ara-G), 1-O-hexadecylcyloxypropyl-cyclic-cidofovir (HDP-cCDV) or hexadecyloxypropyl-3-phospho-ganciclovir (HDP-P-GCV) in the eye, thereby increasing residence

time of the therapeutically active agent in ocular tissue comprising intravitreally injecting a solution of microfluidized particles of HDP-P-Ara-G, microfluidized particles of HDP-P-cCDV or microfluidized particles of HDP-GCV to the eye, wherein the microfluidized particles of HDP-P-Ara-G, and the microfluidized particles of HDP-P-cCDV, and the microfluidized particles of HDP-GCV have a volume median diameter of about 4.4 μm , with the proviso that the method does not use liposomes.

25-63. (Canceled).